Legislature(2013 - 2014)BUTROVICH 205
02/21/2014 01:30 PM Senate HEALTH & SOCIAL SERVICES
| Audio | Topic |
|---|---|
| Start | |
| SB169 | |
| SB162 | |
| SB161 | |
| SB151 | |
| Adjourn |
* first hearing in first committee of referral
+ teleconferenced
= bill was previously heard/scheduled
+ teleconferenced
= bill was previously heard/scheduled
| *+ | SB 169 | TELECONFERENCED | |
| *+ | SB 162 | TELECONFERENCED | |
| + | TELECONFERENCED | ||
| = | SB 161 | ||
| = | SB 151 | ||
SB 169-STATEWIDE IMMUNIZATION PROGRAM
1:32:41 PM
CHAIR STEDMAN announced that the first order of business would
be SB 169. He said it is the first hearing on the bill. The
intent is to adopt a new Committee Substitute, have the sponsor
introduce the bill, take public testimony, and then set the bill
aside for further review.
1:32:47 PM
SENATOR MEYER moved to adopt the CS for SB 169, labeled 28-
LS1219\P, as the working document.
CHAIR STEDMAN objected for discussion purposes.
SENATOR CATHY GIESSEL, Alaska State Legislature, Juneau, Alaska,
sponsor of SB 169, introduced the bill. She stated that SB 169
would permanently put the state vaccine program in place with
monies other than the state's money. She related that after
Senator Stevens left the U.S. Senate, the Center for Disease
Control changed how they viewed Alaska. Alaska had been getting
$4.3 million per year to provide vaccines for all residents.
That funding decreased to $700,000. The state's vaccination
program was greatly curtailed. She recalled the vaccine-
preventable diseases that the program targeted.
SENATOR GIESSEL related that two years ago, after hearing this
same bill, the state funded the program for $4 million per year
for 3 years. At the end of 3 years, the Department of Health and
Social Services (DHSS) was charged with finding a way to fund
the program, in collaboration with the state's insurance
companies. She said that is what this bill does.
1:35:45 PM
JANE CONWAY, Staff, Senator Cathy Giessel, Alaska State
Legislature, Juneau, Alaska, described the changes in SB 169 on
behalf of the sponsor. She said changes were made from version O
to version P, the current CS. She noted the original bill used
the name "State Vaccine Assessment Commission" for the group
being set up to administer the vaccine program. That name was
changed to the "State Vaccine Assessment Council" so it would
not be confused with the current "State Health Care Commission."
All throughout the bill the term was changed. Another term was
changed in version P; "health care insurer" was changed to "an
assessable entity" for a broader usage. It is a term used by
other states for their vaccine assessment programs.
MS. CONWAY referred to page 5, line 18; the manner in which the
definition "assessable entity" is written is different than
version O, but is using the same reference by definition and it
encompasses the detail list from version O. This language
recommended by legislative legal services.
CHAIR STEDMAN removed his objection to adopting version P. There
being no objection, version P was before the committee.
1:38:10 PM
At ease
1:39:42 PM
SENATOR MEYER inquired about the change in wording from
"commission" to "council." He asked if the council would be
treated like a commission in the sense that people from all over
the state make up the members, they meet on a regular basis, and
are subject to an audit.
MS. CONWAY explained that the council is a group that is
appointed by the commissioner of Public Health; it is not a
board. The council will meet throughout the year to set up the
program and assess the entities. They will work under the
auspices of DHSS and they will serve without compensation or
reimbursement.
SENATOR MEYER asked if they would serve at the pleasure of the
commissioner.
MS. CONWAY said the commissioner of DHSS would appoint an 8-
member board.
1:42:04 PM
WARD HURLBERT, Chief Medical Officer, Division of Public Health,
Department of Health and Social Services (DHSS), Juneau, Alaska,
provided information related to SB 169. He shared a story to
highlight the vast changes from vaccinations in Alaska. He said
in 1953 in Ketchikan there were 93 cases of polio, 83 of which
were paralytic. Today, a woman came in and was resistant to
having her child immunized because she did not know what polio
was. He told a story about a measles outbreak in Dillingham in
1961 when children died from the disease. He said it has been a
long time since an Alaskan has been lost to measles, due to
vaccinations.
DR. HURLBERT shared data about the effectiveness of
vaccinations. The flu vaccine is only about 50 percent to 60
percent effective for those over 65 years old. Worldwide,
smallpox no longer exists. It is nearly the same with polio. He
concluded that immunizations have made a big difference.
1:44:56 PM
He explained that the proposed methodology in the bill is used
by 9 other states. He called it a "win/win" because the payers
have to pay less because the state will buy vaccinations at
wholesale rates. The modest surcharge will pay for vaccines for
underinsured children. About five years ago Alaska was 49th
among states in immunization rates for ages two and under.
Currently, Alaska is 37th or 38th and about 65 percent of kids
are immunized. He predicted that this legislation would improve
these numbers much like New Hampshire was able to do.
1:46:29 PM
ROSALYN SINGLETON, M.D., representing herself, Anchorage,
Alaska, testified in support of SB 169. She called the bill a
cost-saving model which will improve access to vaccines for all
Alaskans, streamline the distribution of vaccines, and reduce
the huge administrative burden that health providers currently
have. She said vaccinations demonstrated the dramatic effect of
reducing Hepatitis A from the highest to the lowest rate in the
country. Also, Alaska has been free of measles since 2000.
She said Alaska's expanse challenges the ability to provide on-
time immunizations, so ready access to vaccines is critical. Due
to the administrative burden, some providers in small
communities no longer can provide all of the recommended
vaccines due to having to front costs and keep separate stocks
of vaccine from state and private purchases. She remarked that
she has received calls from providers and parents who cannot
access vaccines.
She said other states have experienced cost savings and
streamlined distribution when using the model the bill would
create.
1:49:28 PM
LILY LOU, M.D., Medical Director, Newborn Intensive Care Unit,
Providence Children's Hospital, Anchorage, Alaska, testified in
support of SB 169. She shared that she is the president of the
Alaska Chapter of the American Academy of Pediatrics (AAP) and
the District 8 representative, for the Western United States and
Canada, to the executive committee of the AAP section on
perinatal pediatrics. She said she is speaking as an individual
in favor of the bill for four reasons. First, is the
effectiveness of vaccines, second, is good stewardship, third,
is access to care, and fourth, is the future.
DR. LOU related that the prevention of infectious diseases by
immunization has been one of the most significant advances in
health care in human history. She shared statistics related to
16 measles outbreaks in 2011, the cost of which was estimated to
be $5.3 million. She maintained that vaccinations will protect
everyone and a universal purchase program will likely lead to
savings.
She said a vaccine assessment account will allow the state to
benefit from volume purchasing at discounted federal rates.
Other states have shown significant savings and have streamlined
the process. The new system will provide more access to care,
especially in small communities. It will also have a positive
effect on the future.
1:54:04 PM
PATRICIA SENNER, Director, Professional Practices, Alaska Nurses
Association, Anchorage, Alaska, testified in support of SB 169.
She spoke of frustrations she has experience as a nurse
practitioner providing immunizations since the state moved away
from universal coverage. She said she had to keep separate sets
of vaccines for those eligible and not eligible for vaccines
through the state. That made for increased costs and increased
administrative difficulties, as well as for waste.
1:55:54 PM
RANDI SWEET, representing herself, Anchorage, Alaska, testified
in support of SB 169.
1:56:37 PM
AMY DRESSEL, Pediatrician, Juneau, Alaska, testified in support
of SB 169. She listed many reasons for supporting the bill. She
said vaccines are very expensive and there are problems with
access. The bill helps all vaccine-eligible children in Alaska.
Alaska is lowest on the national vaccine record. The bill would
help all Alaskans, provide favorable rates, and universal
access, decrease the administrative burden, and make for a more
efficient system.
1:59:06 PM
CHAIR STEDMAN closed public testimony.
CHAIR STEDMAN detailed five fiscal notes: one fiscal note that
reflects the fund transfer to the new vaccine assessment account
in the amount of $4,496,000 from an appropriation in the
Governor's current FY 15 budget; one net zero fiscal note from
the Department of Health and Social Services (DHSS), Public
Health Division, showing the program's expenses of $26,950,000
and the same amount in program revenue; and one indeterminate
fiscal note from the Department of Health and Social Services
(DHSS), Medicaid Service Division; one zero fiscal note from the
Department of Commerce, Community and Economic Development
(DCCED); and one indeterminate fiscal note from the Department
of Administration.
2:00:34 PM
SENATOR MICCICHE asked if it was an initial $4.4 million to fund
the program and then about $33,000 in fees to make it
sustainable.
MS. CONWAY clarified that $4 million is left over in the vaccine
program now and will be transferred to the new model. That
amount will help to purchase the initial vaccine for the next
year. The department will then use a formula to assess how many
vaccines will be needed statewide and purchase them in bulk with
money from the assessable entities. After the initial $4 million
the program becomes funded by insurance payers.
SENATOR MICCICHE stated that $4.4 million is leftover previous
funding.
MS. CONWAY said correct.
CHAIR STEDMAN held SB 169 in committee.
| Document Name | Date/Time | Subjects |
|---|---|---|
| CSSB169 vsn P.pdf |
SHSS 2/21/2014 1:30:00 PM |
SB 169 |
| SB 169 3 Support Letters.pdf |
SHSS 2/21/2014 1:30:00 PM |
SB 169 |
| SB 169 DCCED fiscal note.pdf |
HHSS 4/8/2014 3:00:00 PM SHSS 2/21/2014 1:30:00 PM |
SB 169 |
| SB 169 DHSS fiscal note #2.pdf |
HHSS 4/8/2014 3:00:00 PM SHSS 2/21/2014 1:30:00 PM |
SB 169 |
| SB 169 DHSS fiscal note.pdf |
HHSS 4/8/2014 3:00:00 PM SHSS 2/21/2014 1:30:00 PM |
SB 169 |
| SB 169 DOA fiscal note.pdf |
HHSS 4/8/2014 3:00:00 PM SHSS 2/21/2014 1:30:00 PM |
SB 169 |
| SB 169 Fund Transfers fiscal note.pdf |
HHSS 4/8/2014 3:00:00 PM SHSS 2/21/2014 1:30:00 PM |
SB 169 |
| SB 169 Dr. Brown support letter.pdf |
SHSS 2/21/2014 1:30:00 PM |
SB 169 |
| SB 169 Support Atwood.pdf |
SHSS 2/21/2014 1:30:00 PM |
SB 169 |
| SB 169 Support Brand.pdf |
SHSS 2/21/2014 1:30:00 PM |
SB 169 |
| SB 169 Support Letters.pdf |
SHSS 2/21/2014 1:30:00 PM |
SB 169 |
| SB 169 Support Singleton.pdf |
SHSS 2/21/2014 1:30:00 PM |
SB 169 |
| SB 169 vsn O.pdf |
SHSS 2/21/2014 1:30:00 PM |
SB 169 |
| SB169 AKVax ScheduleKids.pdf |
SHSS 2/21/2014 1:30:00 PM |
SB 169 |
| SB169 Sectional Analysis.pdf |
SHSS 2/21/2014 1:30:00 PM |
SB 169 |
| SB169 Sponsor Statement Immunization Program.pdf |
HHSS 4/8/2014 3:00:00 PM SHSS 2/21/2014 1:30:00 PM |
SB 169 |
| SB169 Support Anch Pediatric.pdf |
SHSS 2/21/2014 1:30:00 PM |
SB 169 |
| SB169 Support Jacob.pdf |
SHSS 2/21/2014 1:30:00 PM |
SB 169 |
| SB169 Support Woodard.pdf |
SHSS 2/21/2014 1:30:00 PM |
SB 169 |
| SB169 Vaccines In AK short vsn.pptx |
SHSS 2/21/2014 1:30:00 PM |
SB 169 |
| SB169 VaxBenefit CostRatio.pdf |
SHSS 2/21/2014 1:30:00 PM |
SB 169 |
| SB169 VaxFundsNonFedMap Adults_AIM.pdf |
SHSS 2/21/2014 1:30:00 PM |
SB 169 |
| SB169 VaxFundsNonFedMapKids_AIM.pdf |
SHSS 2/21/2014 1:30:00 PM |
SB 169 |
| SB169 VaxSupply MapKids_AIM.pdf |
SHSS 2/21/2014 1:30:00 PM |
SB 169 |
| SB169 WhoPaysFor VaccineInAK.pdf |
HHSS 4/8/2014 3:00:00 PM SHSS 2/21/2014 1:30:00 PM |
SB 169 |
| SB169FAQ1pg_16Feb2014.pdf |
SHSS 2/21/2014 1:30:00 PM |
SB 169 |
| SB169FlowChart10_Feb2014.pdf |
SHSS 2/21/2014 1:30:00 PM |
SB 169 |
| SB 162 - Blower support.pdf |
SHSS 2/21/2014 1:30:00 PM |
SB 162 |
| SB 162 - Dobson support letter.pdf |
SHSS 2/21/2014 1:30:00 PM |
SB 162 |
| SB 162 - Epidemiology bulletin.pdf |
SHSS 2/21/2014 1:30:00 PM |
SB 162 |
| SB 162 - FDA announcement.pdf |
SHSS 2/21/2014 1:30:00 PM |
SB 162 |
| SB 162 - Lentfer support.pdf |
SHSS 2/21/2014 1:30:00 PM |
SB 162 |
| SB 162 - Sponsor Statement.docx |
SHSS 2/21/2014 1:30:00 PM |
SB 162 |
| SB 162 AAO letter.pdf |
SHSS 2/21/2014 1:30:00 PM |
SB 162 |
| SB 162 AK Optometric Assoc support letter.pdf |
SHSS 2/21/2014 1:30:00 PM |
SB 162 |
| SB 162 ASAM letter.pdf |
SHSS 2/21/2014 1:30:00 PM |
SB 162 |
| SB 162 DCCED fiscal note.pdf |
SHSS 2/21/2014 1:30:00 PM |
SB 162 |
| AK SB 169_BIO Letter_2 21 14 Final.pdf |
SHSS 2/21/2014 1:30:00 PM |
SB 169 |
| SB 169 AaNA and Dr. Lou testimony.pdf |
SHSS 2/21/2014 1:30:00 PM |
SB 169 |
| CSSB 169(HSS).pdf |
SHSS 2/21/2014 1:30:00 PM |
SB 169 |